TVTX today
$51.56-$0.48 (-0.92%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourBearish
15 minBearish
5 minDescending Triangle
Daily trend turns up above $52.87
Key levels
Resistance$55.57
Resistance$52.87
Support$49.24
Support$44.73
Latest news & SEC filings
AnalystLeerink Partners keeps Outperform on Travere Therapeutics, cuts target to $67
AnalystCanaccord Genuity keeps Buy rating on Travere Therapeutics, lifts target to $72
All TVTX news →About Travere Therapeutics
Travere Therapeutics is a biopharmaceutical company that develops treatments for uncommon kidney and metabolic disorders. Its main product, FILSPARI, is cleared for use in the United States and Europe in adults with primary IgA nephropathy who face worsening kidney function, and it is also being reviewed by U.S. regulators for another kidney condition, FSGS. The company is developing pegtibatinase for classical homocystinuria and has partners handling sparsentan in Europe and parts of Asia.
Based on the company's 10-K filed Feb 19, 2026.
Nasdaq · Healthcare
Travere Therapeutics, Inc. (TVTX)
What Is the Price Target for TVTX?
SEPT Low Target
$65.00
SEPT Mid Target
$72.00
SEPT High Target
$85.00
Analyst Consensus
$72.00
Is TVTX a Buy or Sell Right Now?
Thesis
- •Revenue growing 110.5% YoY with ACCELERATING trend — accelerating momentum.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TVTX.
Start Free Trial →Is TVTX Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$54.16
19
Moat Score
NONE
6/9
Piotroski Score
3.0
Altman Z-Score
What Is Smart Money Doing with TVTX?
Insider Signal
SELLING
0 buys / 14 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| REED ELIZABETH E | officer | Buy | 37,500 | $580K | Sep 15, 2026 |
| REED ELIZABETH E | officer | Sale | 21,926 | $1.4M | Sep 15, 2026 |
| REED ELIZABETH E | officer | Sale | 13,874 | $869K | Sep 15, 2026 |
| REED ELIZABETH E | officer | Sale | 1,400 | $89K | Sep 15, 2026 |
| REED ELIZABETH E | officer | Sale | 300 | $20K | Sep 15, 2026 |
| Meckler Jeffrey A | director | Buy | 10,000 | $174K | Sep 10, 2026 |
| Meckler Jeffrey A | director | Sale | 1,700 | $111K | Sep 10, 2026 |
| Meckler Jeffrey A | director | Sale | 1,200 | $79K | Sep 10, 2026 |
| Meckler Jeffrey A | director | Sale | 14,000 | $944K | Sep 10, 2026 |
| Meckler Jeffrey A | director | Sale | 3,100 | $211K | Sep 10, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →TVTX Growth Story
Revenue YoY
110.5%
3yr Revenue CAGR
64.9%
EPS Growth YoY
92.89%
FCF Growth YoY
N/A%
Revenue Trend
ACCELERATING
Dark Pool Trades for TVTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for TVTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:46 | $51.56 | 2,554 | $$132K | SELL |
| 21:00:22 | $51.56 | 4,199 | $$217K | SELL |
| 21:00:22 | $51.56 | 4,099 | $$211K | SELL |
| 21:00:22 | $51.56 | 1,500 | $$77K | SELL |
| 21:00:00 | $51.56 | 1,371 | $$71K | SELL |
5 dark pool trades shown · $$708K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Travere Therapeutics, Inc. (TVTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →TVTX — frequently asked questions
What is TVTX stock price today?
Travere Therapeutics, Inc. (TVTX) is at $51.56, down 0.92% (-$0.48) at the Nov 12, 2026 close.
Why is TVTX stock moving today?
Latest TVTX news — Nov 5, 2026: Leerink Partners keeps Outperform on Travere Therapeutics, cuts target to $67 · Nov 4, 2026: Canaccord Genuity keeps Buy rating on Travere Therapeutics, lifts target to $72
What is the TVTX price target?
The average analyst price target for TVTX is $72.00, ranging from $65 to $85, based on 11 analysts. Latest: Leerink Partners maintains on Nov 5, 2026.
What do analysts rate TVTX?
Analyst ratings for TVTX: 0 Buy, 34 Hold, 0 Sell — consensus Hold.
Did TVTX beat earnings?
TVTX last reported on Nov 2, 2026: EPS -$0.55 vs -$0.10 expected — a miss of 458.9%.
Does TVTX pay a dividend?
TVTX does not currently pay a dividend.
What are TVTX support and resistance levels?
Support: $49.24, $44.73, $41.32. Resistance: $52.87, $55.57, $58.32.
What are insiders doing with TVTX?
Insider activity: SELLING, 0 buys and 14 sells in the last 90 days.
What is the latest news on TVTX?
Nov 5, 2026: Leerink Partners keeps Outperform on Travere Therapeutics, cuts target to $67 · Nov 4, 2026: Canaccord Genuity keeps Buy rating on Travere Therapeutics, lifts target to $72